The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II drugs for Pheochromocytoma have a 33% phase transition ...

BACKGROUND: There are limitations to currently available biochemical tests for pheochromocytoma. Our objective was to evaluate the diagnostic efficacy of a novel tandem mass spectrometry assay for ...

Family history or certain types of symptom profiles might indicate to a doctor that a pheochromocytoma may be present. These tumors are also linked to certain, rare genetic conditions. Diagnosis ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

DeBakey VA Medical Center in Houston. “You also can’t overlook the fact that “there’s a lot of uncertainty in diagnosis,” Schiff says. There are several thousand known diseases but only so many ...